On Wednesday, Jasper Therapeutics (NASDAQ:JSPR) stock received an Outperform rating with a price target set at $65.00 by Evercore ISI. The firm highlighted the company’s transition to the public market via a SPAC in late 2021 and its current focus on developing briquilimab for mast-cell driven disorders. Jasper’s lead program, briquilimab, is a c-Kit antibody initially in-licensed from AMGN, previously aimed at conditioning for cell transplants.
The company has shifted its primary focus toward treating chronic urticaria, anticipating initial data from clinical studies in 3Q24. The analyst pointed out the clinical success of a similar approach by CLDX, noting its efficacy and unexpectedly clean safety profile. This positive outlook is based on the premise that Jasper Therapeutics’ strategy is underpinned by CLDX’s clinical achievements.
Jasper Therapeutics’ pivot towards mast-cell driven disorders represents a strategic move within the biopharmaceutical industry, aiming to address a specific patient population with chronic urticaria. The company’s progress and upcoming clinical data release in the third quarter of 2024 are now key milestones for investors and industry watchers.
The price target of $65.00 suggests a significant upside potential for Jasper Therapeutics’ stock, reflecting the analyst’s confidence in the company’s therapeutic program and its potential market impact.
InvestingPro Insights
As Jasper Therapeutics (NASDAQ:JSPR) garners attention with its Outperform rating and a lofty price target of $65.00, a glance at the real-time data from InvestingPro provides a broader perspective on the company’s financial health and stock performance. With a market capitalization of approximately $394.67 million and a notably high price to book ratio of 5.03 as of Q4 2023, investors are valuing the company’s assets aggressively relative to its equity. Despite the absence of profitability, as indicated by a negative P/E ratio of -6.12 for the last twelve months as of Q4 2023, Jasper’s stock has experienced an impressive price total return of 274.82% over the last three months, and 253.1% over the last six months.
InvestingPro Tips highlight that Jasper holds more cash than debt on its balance sheet, which is a positive sign for financial stability. Additionally, the company’s liquid assets surpass short-term obligations, suggesting a healthy liquidity position. However, analysts do not expect the company to be profitable this year, and the stock has suffered from weak gross profit margins and high volatility in price movements. For investors seeking more in-depth analysis, there are 10 additional InvestingPro Tips available at: https://www.investing.com/pro/JSPR. Utilize the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking further insights to inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
